Bastard J P, Bruckert E, Robert J J, Ankri A, Grimaldi A, Jardel C, Hainque B
Laboratoire de Biochimie B, Hôpital Salpétrière, Paris, France.
Int J Obes Relat Metab Disord. 1995 Nov;19(11):836-8.
Plasminogen activator inhibitor 1 (PAI-1) levels are elevated in obese insulin-resistant subjects. However the mechanism underlying increased PAI-1 levels is unknown. To determine the impact of diabetes on PAI-1 levels and its possible relationship to insulin resistance, hyperinsulinemic euglycemic clamp studies were performed in nine lean control subjects, nine non-diabetic obese subjects and eight obese patients with NIDDM. Fasting plasma PAI-1 levels were 4.0 to 4.7 fold higher in the two obese groups than in the control group. During the 40 mU/m2 x min insulin infusion, suppression of FFA concentration was correlated with fasting plasma PAI-1 levels in both obese non-diabetic and obese NIDDM subjects. It is concluded that (1) obesity rather than diabetes itself plays a major role for the increased PAI-1 levels in NIDDM; (2) resistance to the antilipolytic effect of insulin, resulting in increased FFA concentrations, may participate in producing elevated PAI-1 levels in android obese subjects.
纤溶酶原激活物抑制剂1（PAI-1）水平在肥胖的胰岛素抵抗受试者中升高。然而，PAI-1水平升高的潜在机制尚不清楚。为了确定糖尿病对PAI-1水平的影响及其与胰岛素抵抗的可能关系，对9名瘦的对照受试者、9名非糖尿病肥胖受试者和8名非胰岛素依赖型糖尿病肥胖患者进行了高胰岛素正常血糖钳夹研究。两个肥胖组的空腹血浆PAI-1水平比对照组高4.0至4.7倍。在40 mU/m2×min胰岛素输注期间，肥胖非糖尿病和肥胖非胰岛素依赖型糖尿病受试者中游离脂肪酸（FFA）浓度的抑制与空腹血浆PAI-1水平相关。得出以下结论：（1）在非胰岛素依赖型糖尿病中，肥胖而非糖尿病本身对PAI-1水平升高起主要作用；（2）对胰岛素抗脂解作用的抵抗导致FFA浓度升高，可能参与导致男性型肥胖受试者PAI-1水平升高。
